Galapagos NV Stock News

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV (“Galapagos” or the “Company”) (NASDAQ: GLPG).   Such investors are

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contac

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q3 2020 Results - Earnings Call Transcript

Gilead Sciences recently announced the FDA response from Filgotinib, responses that put the future of the multi-billion drug program in doubt.

G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA. Gilead suffers setback on filgotinib NDA front.

Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contact Robert S. Willoughby at newaction@poml

What happened Shares of Galapagos (NASDAQ: GLPG) were crashing 24.6% lower as of 11:14 a.m. EDT on Wednesday. The big drop came after the biotech's partner, Gilead Sciences (NASDAQ: GILD), announced t

(Bloomberg) -- The Food and Drug Administration’s rejection of a pair of medicines that Wall Street expected to sail by regulators raised concerns that other upcoming drug decisions could meet a sim

The Food and Drug Administration rejected Gilead Sciences’ application for a would-be blockbuster arthritis drug Tuesday night, blindsiding investors.

Gilead Sciences investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S. Food and Drug Administration in current form, its partner Galapagos sai

Gilead Sciences (GILD) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment fo

Gilead Sciences, Inc (NASDAQ: GILD) shares took a jolt in the after-hours session Tuesday as it announced its application for filgotinib, an investigational treatment for moderately to severely active

* * * Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete respons